U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H24NO2S.CH3O4S
Molecular Weight 429.551
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIEMONIUM METHYLSULFATE

SMILES

COS([O-])(=O)=O.C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3

InChI

InChIKey=JPOKDEDHVLJMIJ-UHFFFAOYSA-M
InChI=1S/C18H24NO2S.CH4O4S/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16;1-5-6(2,3)4/h2-8,15,20H,9-14H2,1H3;1H3,(H,2,3,4)/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C18H24NO2S
Molecular Weight 318.454
Charge 1
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula CH3O4S
Molecular Weight 111.097
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds.
2010-03
Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide.
2009-08-06
Orofacial dyskinesia associated with tiemonium.
2007-12
Patents

Sample Use Guides

Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.
Route of Administration: Other
Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:51:44 GMT 2025
Edited
by admin
on Mon Mar 31 20:51:44 GMT 2025
Record UNII
8PYN0UZM30
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIEMONIUM METHYLSULPHATE
WHO-DD  
Preferred Name English
TIEMONIUM METHYLSULFATE
Common Name English
Tiemonium methylsulphate [WHO-DD]
Common Name English
MORPHOLINIUM, 4-(3-HYDROXY-3-PHENYL-3-(2-THIENYL)PROPYL)-4-METHYL-, METHYL SULFATE (1:1)
Systematic Name English
Tiemonium mesilate [WHO-DD]
Common Name English
Code System Code Type Description
CAS
6504-57-0
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
ECHA (EC/EINECS)
229-386-0
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
PUBCHEM
151420
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
EVMPD
SUB15571MIG
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
RXCUI
38265
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID40983580
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
FDA UNII
8PYN0UZM30
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
SMS_ID
100000085028
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
MESH
C020526
Created by admin on Mon Mar 31 20:51:44 GMT 2025 , Edited by admin on Mon Mar 31 20:51:44 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY